WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2023-04-1810,000$36.00
$360.00kSell
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2023-04-1810,000$18.41
$184.10kBuy
Helen TorleyPRESIDENT AND CEO2023-03-0910,000$14.66
$146.60kBuy
Helen TorleyPRESIDENT AND CEO2023-03-0910,000$42.73
$427.27kSell
Helen TorleyPRESIDENT AND CEO2023-03-0810,000$14.66
$146.60kBuy
Helen TorleyPRESIDENT AND CEO2023-03-0810,000$43.26
$432.59kSell
Helen TorleyPRESIDENT AND CEO2023-03-0710,000$14.66
$146.60kBuy
Helen TorleyPRESIDENT AND CEO2023-03-0710,000$45.47
$454.69kSell
Jeffrey William HendersonDirector2023-03-0110,000$47.71
$477.10kSell
Jeffrey William HendersonDirector2023-02-2810,000$48.51
$485.10kSell

1 of 7

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk20.23%26,633,924$884.25MInsider
Blackrock Inc13.78%18,145,852$602.44MInstitution
Vanguard Group Inc10.27%13,519,639$448.85MInstitution
Artisan Partners Limited Partnership5.31%6,992,189$232.14MInstitution
State Street Corp4.52%5,954,775$197.70MInstitution
Snyder Capital Management L P3.26%4,295,184$142.60MInstitution
Gregory Ian Frost2.77%3,641,380$120.89MInsider
Jpmorgan Chase Co2.68%3,522,776$116.96MInstitution
Invesco Ltd2.65%3,491,177$115.91MInstitution
Macquarie Group Ltd2.43%3,200,481$106.26MInstitution

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO78.03%21.97%Net SellingNet Selling
PCVX80.84%19.16%Net SellingNet Selling
DNLI55.65%44.35%Net SellingNet Buying
TGTX54.98%45.02%Net Selling
ACAD70.81%29.19%Net BuyingNet Buying
View Top Biotech Stocks

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 92.96% institutional shareholders, 26.18% Halozyme Therapeutics insiders, and 0.00% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 20.23% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $884.25M.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.